Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants
Tóm tắt
The incidence of candidiasis among immunocompromised patients and emergence of antimycotics resistant strains has increased significantly. The aims of this study were: to examine the in vitro activity of antimycotics and biocides against Candida clinical isolates; to detect cross-resistance of fungi to these preparations and to estimate whether disinfectants applied in hospital areas are active against clinical Candida isolates. In vitro susceptibility of 102 Candida isolates to eight antimycotics was examined by Etest and ATB Fungus. Sensitivity of these strains to four disinfectants and an antiseptic agent was tested according to EN 1275:2005. Amphotericin B, caspofungin and 5-fluorocytosine were the most effective antimycotics against all Candida isolates. Resistance to itraconazole and fluconazole was observed among C. krusei and C. glabrata. The MICs (Minimal Inhibitory Concentrations) for ketoconazole, voriconazole and posaconazole against Candida albicans ranged: 0.003 - >32 μg/ml and one strain was resistant to three agents tested. All analysed Candida strains were sensitive to biocides containing either chlorine, aldehyde, alcohol mixtures, glucoprotamin or chlorhexidine gluconate with isopropanol. Sensitivity to these agents was observed at concentrations lower than those concentrations recommended by manufacturers to achieve proper biocidal activity to those preparations. Our data suggest that these disinfectants can be effectively applied in clinical wards to prevent nosocomial Candida infections.
Tài liệu tham khảo
Colombo A.L, Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al., Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-bind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis, Eur. J. Clin. Microbiol. Infect. Dis., 2003, 22, 470–474
Hobson R.P., The global epidemiology of invasive Candida infections - is the tide turning?, J. Hosp. Infect., 2003, 55, 159–168
Schelenz S., Management of candidiasis in the intensive care unit, J. Antimicrob. Chemother., 2008, 61, i31–i34
Elie Ch.M., Lott T.J., Reiss E., Morrison Ch.J., Rapid identification of Candida species with species-specific DNA probes, J. Clin. Microbiol., 1998, 36, 3260–3265
Gualco L., Debbia E.A., Bandettini R., Pescetto L., Cavallero A., Ossi M. C., et al., Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults, Int. J. Infect. Dis., 2007, 29, 179–184
Swinne D., Watelle M., Van der Flaes M., Nolard N., In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study), Mycoses, 2004, 47, 177–183
Safdar A., Chaturvedi V., Koll B.S., Larone D.H., Perlin D.S., Armstrong D., Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles to bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida susceptibility trends study, 1998 to 1999), Antimicrob. Agents Chemother., 2002, 46, 3268–3272
Espinel-Ingroff A., Boyle K., Sheehan D.J., In vitro activities of voriconazole an reference agents as determined by NCCLS methods: review of the literature, Mycopathologia, 2001, 150, 101–115
Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., Jones R.N., The International Fungal Surveillance Participant Group, In vitro activities of voriconazole, posaconazole and four licensed systemic antifungal agents against Candida species infrequently isolated from blood, J. Clin. Microbiol., 2003, 41, 78–83
Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schönheyder H.C., Knudsen J.D., Jensen I.M., et al., Semi-national surveillance of fungemia in Denmark 2004-2006; increasing incidence of fungemia and numbers of isolates with reduced azole susceptibility, Clin. Microbiol. Infect., 2008, 14, 487–494
Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R., Candidaemia in Europe: epidemiology and desistance, Int. J. Antimicrob. Agents., 2006, 27, 359–366
Quindos G., Sanchez-Vargas L.O., Villar-Vidal M., Eraso E., Alkorta M., Hernandez-Almaraz J.L., Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre, Int. J. Antimicrob. Agents, 2008, 31, 266–271
Falagas M.E., Ntziora F., Betsi G.I., Samonis G., Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials, Int. J. Antimicrob. Agents, 2007, 29, 136–143
Patterson T.F., Patterson J.F., Fungistatic and fungicidal compounds for human pathogens, In: Block S.S., (Ed.), Disinfection, Sterilization, and Preservation, 5th Ed., Lippincott Willams & Wilkins, Philadelphia, 2001, 617–639
Penna T.C., Mazzola P.G., Martins A.M, The efficacy of chemical agents in cleaning and disinfection programs, BMC Infect. Dis., 2001, 1, 16–23
Staniszewska M., Jakimiak B., Rohm-Rodowald E., Bocian E., Kurzątkowski W., Tyski S., Antifungal agents: susceptibility of different fungal strains to various disinfecting agents, Mikol. Lek., 2009, 16, 210–214
European Committee for Standardization; EN 1275: 2005: Chemical disinfectants and antiseptics-Quantitative suspension test for the evaluation of basic fungicidal or basic yeasticidal activity of chemical disinfectants and antiseptics - Test method and requirements (phase 1), Brussels, France
Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd Ed., M27-A3, vol. 28, Clinical and Laboratory Standards Institute, Pennsylvania, 2008
Maxwell M.J., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Diekema D.J., et al., International Fungal Surveillance Participant Group, Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical Isolates of Candida Species infrequently isolated from blood, J. Clin. Microbiol., 2003, 41, 1087–1090
Krogh-Madsen M., Arendrup M.C., Heslet L., Knudsen J.D., Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient, Clin. Infect. Dis., 2006, 42, 938–944
Wakieć R., Prasad R., Morschhäuser J., Barchiesi F., Borowski E., Milewski S., Voriconazole and multidrug resistance in Candida albicans, Mycoses, 2007, 50, 109–115
Terleckyj B., Axler D.A., Qantitative neutralization assay of fungicidal activity of disinfectants, Antimicrob. Agents Chemother., 1987, 31, 794–798
McDonnell G., Russell A.D., Antiseptics and disinfectants: Activity, Action, and Resistance, Clin. Microbiol. Rev., 1999, 12, 147–179